Clinical Trial Update: A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors. [Phase 1]

View source ↗

Summary

Phase 1 study evaluating multiple ascending doses of the investigational cancer agent R4733 in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• R4733

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neoplasms | Phase 1 | Status: COMPLETED